No Data
No Data
H.C. Wainwright Maintains Checkpoint Therapeutics(CKPT.US) With Buy Rating, Maintains Target Price $20
Checkpoint Therapeutics Announces Cosibelimab Longer-Term Results in Advanced Cutaneous Squamous Cell Carcinoma Presented at ESMO Congress 2024
Checkpoint Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
Check Point Software To Acquire Cyberint To Transform Security Operations; No Financial Terms Of The Transaction Disclosed
Checkpoint Therapeutics Unveils Secondary Sale of Securities
What Makes Checkpoint Therapeutics (CKPT) a New Buy Stock
No Data
No Data